AI Article Synopsis
- Weaning from cardiopulmonary bypass is a critical phase in mitral valve surgery, particularly for patients with severe pulmonary hypertension.
- Two patients with severe pulmonary hypertension underwent surgery for valvular heart disease, during which the drug levosimendan was utilized to lower pulmonary artery pressure due to its beneficial vasodilatory and cytoprotective effects.
- Both patients successfully tolerated the operation and the administration of levosimendan, resulting in an uncomplicated postoperative recovery, highlighting the drug’s effectiveness in managing pulmonary hypertension during heart valve surgeries.
Article Abstract
Weaning from cardiopulmonary bypass is the most important stage during mitral valve surgery, especially in patients with severe pulmonary hypertension. We report two patients with severe pulmonary hypertension who were operated on because of valvular heart disease. To reduce the pulmonary artery pressure, levosimendan was used because of its vasodilatory and cytoprotective effects. All patients tolerated the operation and levosimendan administration. Their postoperative course was uneventful. Levosimendan can be used to treat pulmonary hypertension during operations for heart valve disease. Patients clearly benefit from the vasodilator action of the drug for reducing pulmonary artery pressure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11748-008-0301-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!